Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist research hub

Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

This study is looking for new ways to treat advanced lung cancer, specifically a type called NSCLC. It's testing a new treatment combination that targets specific proteins in the cancer to see how well it works. This is for adult patients who have certain features in their cancer.